Skip to Content
You are currently on the new version of our website. Access the old version .
MedicinaMedicina
  • Review
  • Open Access

29 April 2022

15 Pages

An Overview of Off-Label Use of Humanized Monoclonal Antibodies in Paediatrics

,
and
1
Paediatrics and Neonatology Unit, San Giuseppe Hospital, 50053 Empoli, Italy
2
Specialty School of Paediatrics, Alma Mater Studiorum, University of Bologna, 40138 Bologna, Italy
3
Paediatrics Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy
*
Author to whom correspondence should be addressed.

Abstract

In recent years, off-label and unlicensed drug use has extensively developed in the paediatric population. For a long time, clinical trials in the paediatric population were considered complicated to perform because of ethical problems, causing frequent off-label use. Off-label drug use remains an important public health issue, especially for children with rare conditions or with diseases not responsive to conventional treatments. The present paper is a narrative review of the literature of off-label drug use in children. The aim of our study is to summarize the main works dealing with the off-label use of biological drugs in paediatrics. Further studies analyzing their efficacy, safety, and cost–benefit ratios are needed to extend the use of biological therapies to the paediatric population.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.